أعرض في EDS

Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’ [European Journal of Cancer 152 (2021) 116-128]

التفاصيل البيبلوغرافية
العنوان: Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’ [European Journal of Cancer 152 (2021) 116-128]
المؤلفون: Vanna Chiarion Sileni, Ashwin Gollerkeri, Dirk Schadendorf, Paolo A. Ascierto, Juliette Murris, Helen Gogas, Naoya Yamazaki, Reinhard Dummer, Caroline Robert, Carmen Loquai, Ralf Gutzmer, Claus Garbe, Abir Tadmouri Sellier, Mario Mandalà, Groot Jan de Willem, Paola Queirolo, Ana Arance, Keith T. Flaherty, Ivana Krajsová, Caroline Dutriaux, Gabriella Liszkay, Jeanne Suissa
المصدر: European Journal of Cancer. 160:287-288
بيانات النشر: Elsevier BV, 2022.
سنة النشر: 2022
مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Melanoma, Cancer, Binimetinib, medicine.disease, chemistry.chemical_compound, Quality of life, chemistry, Internal medicine, medicine, In patient, Open label, business
تدمد: 0959-8049
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::101e41b4fa38018a6fbc59b283ff5710Test
https://doi.org/10.1016/j.ejca.2021.10.002Test
حقوق: OPEN
رقم الانضمام: edsair.doi...........101e41b4fa38018a6fbc59b283ff5710
قاعدة البيانات: OpenAIRE
الوصف
تدمد:09598049